CLEVELAND, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. It is expected that, as a result of the Off ...

Sotera Health Company (NASDAQ:SHC) Q2 2024 Earnings Conference Call August 5, 2024 9:00 AM ET Company Participants Jason Peterson - VP & Treasurer Michael Petras - Chairman & CEO Jonathan Lyons - SVP & CFO Conference Call Participants Dave Windley - Jefferies Brett Fishbin - KeyBanc Capital Markets Patrick Donnelly - Citigroup Inc. Casey Woodring - J.P. Morgan Chase Salem Salem - Barclays Jason Bednar - Piper Sandler Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health Sec ...

Core Insights - Sotera Health Company has appointed Christopher Simon as a new independent director to its Board of Directors, enhancing its leadership team [1][3] - Mr. Simon brings over 30 years of experience in the healthcare industry, including roles as President and CEO of Haemonetics Corporation and Senior Partner at McKinsey & Company [2][3] - Sotera Health operates through three business units: Sterigenics®, Nordion®, and Nelson Labs®, focusing on sterilization solutions and lab testing services for the healthcare sector [4] Company Overview - Sotera Health is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry [4] - The company is committed to its mission of "Safeguarding Global Health®" [4] Leadership Experience - Christopher Simon's leadership experience as a public company CEO and his strategic background in the life sciences industry are expected to be significant assets for Sotera Health's growth [3] - Mr. Simon also serves on the board of directors of AdvaMed, a global trade association for medical technology companies [3]

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company's website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health. Contacts Source: Sotera Health Company To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317- 0709 if dialing-in from other locations. A live webcast of the confe ...

To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317- 0709 if dialing-in from other locations. A live webcast of the conference call can be accessed at this link or via the Investor Relations section of the Company's website at Presentation & Events | Sotera Health, along with the accompanying materials. A replay of the webcast will be available later in the day on August 5th. Jason Peterson Vice President & Treasurer, Sotera Health IR@soterahealth.c ...

Sotera Health Company (NASDAQ:SHC) Q1 2024 Earnings Conference Call May 2, 2024 9:00 AM ET Company Participants Jason Peterson - VP and Treasurer Michael B. Petras - Chairman and CEO Jonathan M. Lyons - SVP and CFO Conference Call Participants Patrick Donnelly - Citigroup Inc. Sean Dodge - RBC Capital Markets Casey Woodring - J.P. Morgan Chase Unidentified Analyst - Barclays Brett Fishbin - KeyBanc Capital Markets Michael Polark - Wolfe Research Operator Good morning, and welcome to the Sotera Health First ...

3 Comprehensive end-to-end services offered (1) Based on revenue for the year ended December 31, 2023. • Nordion supplies high-specific activity (HSA) Cobalt-60 to use in Gamma Knife® radiosurgery for the precision treatment of brain cancer Adjusted EPS(1) $0.00 to $0.13 Business & Market Update Financial Performance • Top- and bottom-line growth compared to Q1 2023 • Completed annual customer satisfaction survey and received continued strong results • NESHAP regulations finalized in March 2024 7 2023 2024 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) If an emerging growth compa ...

Exhibit 99.1 Sterigenics For first-quarter 2024, net revenues were $166 million, an increase of 4.1% compared to the first quarter a year ago. Segment income was $86 million, an increase of 3.6%. Net revenue growth for first-quarter 2024 was driven by favorable pricing and changes in foreign currency exchange rates, partially offset by unfavorable volume and mix. Sotera Health Reports First-Quarter 2024 Results CLEVELAND, OH, May 2, 2024 – Sotera Health Company ("Sotera Health" or the "Company") (Nasdaq: SH ...

Sotera Health Company (NASDAQ:SHC) Q4 2023 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants Jason Peterson - Vice President and Treasurer Michael Petras - Chairman and CEO Jon Lyons - Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Dave Windley - Jefferies Luke Sergott - Barclays Brett Fishbin - KeyBanc Casey Woodring - JPMorgan Patrick Donnelly - Citi Michael Polark - Wolfe Research Operator Good morning and welcome to the Sotera Health Fourth Quarter ...